BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20570743)

  • 41. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development.
    Markert M; Shen R; Trautmann T; Guth B
    J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys.
    Holzgrefe HH; Cavero I; Gleason CR; Warner WA; Buchanan LV; Gill MW; Burkett DE; Durham SK
    J Pharmacol Toxicol Methods; 2007; 55(2):159-75. PubMed ID: 16857392
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs.
    Batey AJ; Doe CP
    J Pharmacol Toxicol Methods; 2002; 48(1):11-9. PubMed ID: 12750037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
    Bass AS; Hanson LA; Jackson TA
    J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An improved method of electrode placement in configuration Lead II for the reliable ECG recording by telemetry in the conscious rat.
    Tontodonati M; Fasdelli N; Dorigatti R
    J Pharmacol Toxicol Methods; 2011; 63(1):1-6. PubMed ID: 20332033
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A canine model used to simultaneously assess potential neurobehavioural and cardiovascular effects of candidate drugs.
    Tontodonati M; Fasdelli N; Moscardo E; Giarola A; Dorigatti R
    J Pharmacol Toxicol Methods; 2007; 56(2):265-75. PubMed ID: 17587603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions.
    Ewart L; Milne A; Adkins D; Benjamin A; Bialecki R; Chen Y; Ericsson AC; Gardner S; Grant C; Lengel D; Lindgren S; Lowing S; Marks L; Moors J; Oldman K; Pietras M; Prior H; Punton J; Redfern WS; Salmond R; Skinner M; Some M; Stanton A; Swedberg M; Finch J; Valentin JP
    J Pharmacol Toxicol Methods; 2013; 68(1):30-43. PubMed ID: 23665080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys.
    Haushalter TM; Friedrichs GS; Reynolds DL; Barecki-Roach M; Pastino G; Hayes R; Bass AS
    Br J Pharmacol; 2008 Aug; 154(7):1457-64. PubMed ID: 18604237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs.
    Polakowski JS; King AJ; Campbell TJ; Nelson RA; Preusser LC; Kempf-Grote AJ; Marsh KC; Gintant GA; Cox BF; Mittelstadt SW
    J Cardiovasc Pharmacol; 2009 Dec; 54(6):543-51. PubMed ID: 19770671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.
    Ewart L; Aylott M; Deurinck M; Engwall M; Gallacher DJ; Geys H; Jarvis P; Ju H; Leishman D; Leong L; McMahon N; Mead A; Milliken P; Suter W; Teisman A; Van Ammel K; Vargas HM; Wallis R; Valentin JP
    Toxicol Sci; 2014 Dec; 142(2):427-35. PubMed ID: 25246669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiorespiratory safety evaluation in non-human primates.
    Ingram-Ross JL; Curran AK; Miyamoto M; Sheehan J; Thomas G; Verbeeck J; de Waal EJ; Verstynen B; Pugsley MK
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):114-24. PubMed ID: 22521338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of cardiovascular changes in dogs administered three positive controls using jacketed external telemetry-blood pressure (JET-BP).
    Kremer JJ; Bills AJ; Hanke NJ; Chen H; Meier WA; Osinski MA; Foley CM
    J Pharmacol Toxicol Methods; 2015; 75():27-37. PubMed ID: 26001324
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of cardiac function in unrestrained dogs and monkeys using left ventricular dP/dt.
    Buchanan LV; Warner WA; Arthur SR; Gleason CR; Lewen G; Levesque PC; Gill MW
    J Pharmacol Toxicol Methods; 2016; 80():51-8. PubMed ID: 27063376
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys.
    McMahon C; Mitchell AZ; Klein JL; Jenkins AC; Sarazan RD
    J Pharmacol Toxicol Methods; 2010; 62(2):127-35. PubMed ID: 20558308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
    Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
    J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds.
    Marks L; Borland S; Philp K; Ewart L; Lainée P; Skinner M; Kirk S; Valentin JP
    Toxicol Appl Pharmacol; 2012 Sep; 263(2):171-83. PubMed ID: 22714037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statistical issues of QT prolongation assessment based on linear concentration modeling.
    Tsong Y; Shen M; Zhong J; Zhang J
    J Biopharm Stat; 2008; 18(3):564-84. PubMed ID: 18470764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium.
    Holzgrefe H; Ferber G; Champeroux P; Gill M; Honda M; Greiter-Wilke A; Baird T; Meyer O; Saulnier M
    J Pharmacol Toxicol Methods; 2014; 69(1):61-101. PubMed ID: 23689033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review of the statistical analysis of the dog telemetry study.
    Aylott M; Bate S; Collins S; Jarvis P; Saul J
    Pharm Stat; 2011; 10(3):236-49. PubMed ID: 20967892
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pharmacokinetic-pharmacodynamic model for cardiovascular safety assessment of R1551.
    Fleury A; Lavé T; Jonsson F; Schmitt M; Hirkaler G; Polonchuk L; Breidenbach A
    J Pharmacol Toxicol Methods; 2011; 63(1):123-33. PubMed ID: 20732434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.